JNJ Jun 2020 110.000 call

OPR - OPR Delayed price. Currency in USD
17.90
+1.84 (+11.46%)
As of 12:26PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close16.06
Open18.15
Bid16.45
Ask19.85
Strike110.00
Expiry date2020-06-19
Day's range17.90 - 18.15
Contract rangeN/A
Volume3
Open interest38
  • J&J's Chief Scientific Officer predicts vaccinations against coronavirus within 12 months
    Yahoo Finance

    J&J's Chief Scientific Officer predicts vaccinations against coronavirus within 12 months

    Johnson & Johnson Chief Scientific Officer Dr. Paul Stoffels predicts the most vulnerable will begin to receive vaccines within 12 months to prevent COVID-19.

  • Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
    Zacks

    Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $119.40, moving +0.18% from the previous trading session.

  • EU says Johnson & Johnson's deal for Takeda patch may harm competition
    Reuters

    EU says Johnson & Johnson's deal for Takeda patch may harm competition

    EU antitrust regulators have opened a full investigation into Johnson & Johnson's acquisition of Takeda Pharmaceutical's surgical patch product TachoSil, concerned that the deal could lead to reduced choice and higher prices for customers. Takeda, Japan's biggest drugmaker, announced the sale of TachoSil, a surgical patch for bleeding control, to U.S. giant Johnson & Johnson's subsidiary Ethicon for $400 million (342 million pounds) last May. The European Commission said a preliminary investigation found cause for concern because TachoSil is the market leader in Europe.

  • Glaxo's Long-Acting HIV Regimen Cabenuva Gets Canada's Nod
    Zacks

    Glaxo's Long-Acting HIV Regimen Cabenuva Gets Canada's Nod

    Glaxo's (GSK) long-acting injectable regimen of cabotegravir and rilpivirine gets its first approval for the treatment of HIV-1 infection in virologically-suppressed adults

  • Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates
    Zacks

    Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates

    Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.

  • Is Johnson & Johnson (NYSE:JNJ) Trading At A 35% Discount?
    Simply Wall St.

    Is Johnson & Johnson (NYSE:JNJ) Trading At A 35% Discount?

    How far off is Johnson & Johnson (NYSE:JNJ) from its intrinsic value? Using the most recent financial data, we'll take...

  • My Top 10 Stock Watch List
    Zacks

    My Top 10 Stock Watch List

    My Top 10 Stock Watch List

  • J&J Files NDA for Multiple Sclerosis Drug Ponesimod in U.S.
    Zacks

    J&J Files NDA for Multiple Sclerosis Drug Ponesimod in U.S.

    Johnson & Johnson's (JNJ) ponesimod's regulatory application in U.S is based on data from the head-to-head OPTIMUM phase III study, comparing it to Sanofi's MS drug, Aubagio.

  • Johnson & Johnson (JNJ) Stock Moves -1.19%: What You Should Know
    Zacks

    Johnson & Johnson (JNJ) Stock Moves -1.19%: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $134.96, moving -1.19% from the previous trading session.

  • Johnson & Johnson (JNJ) Catches Eye: Stock Jumps 7.4%
    Zacks

    Johnson & Johnson (JNJ) Catches Eye: Stock Jumps 7.4%

    Johnson & Johnson (JNJ) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • Calling A Bottom
    Zacks

    Calling A Bottom

    Calling A Bottom

  • Johnson & Johnson: No evidence HIV drug Prezista works against coronavirus
    Yahoo Finance UK

    Johnson & Johnson: No evidence HIV drug Prezista works against coronavirus

    Darunavir (DRV) is a protease inhibitor that goes under the brand name Prezista and is marketed by Janssen.

  • J&J Signs Another Collaboration to Develop Coronavirus Vaccine
    Zacks

    J&J Signs Another Collaboration to Develop Coronavirus Vaccine

    J&J (JNJ) is actively pursuing its development plans related to coronavirus vaccine. The company is partnering with several public/private organizations to accelerate its vaccine development.

  • Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
    Zacks

    Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

  • Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates
    Zacks

    Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates

    Lilly (LLY) signs deal with AbCellera to co-develop antibody therapies to treat COVID-19. AbbVie (ABBV) supports studies evaluating Kaletra for treating COVID-19.

  • Augmented-Reality Startup Magic Leap to Explore a Sale
    Bloomberg

    Augmented-Reality Startup Magic Leap to Explore a Sale

    (Bloomberg) -- Magic Leap Inc., the startup that raised more than $2 billion to build an augmented-reality device, is exploring options including a sale, according to people familiar with the matter.The Plantation, Florida-based company is working with an adviser to consider strategic options that could also include forming a partnership or selling a significant stake ahead of a potential listing, said the people. Magic Leap could fetch more than $10 billion if it pursues a sale, the people said, asking not to be identified because the information is private.Tech companies have been placing bets on the promise of augmented-reality products, which have also found uses in health care and other industries.The entire hardware sector is facing new threats, from tariffs in the U.S.-China trade war to supply chain shortages, after factories closed with the coronavirus outbreak. The pressures are resetting expectations at major companies such as Apple Inc., and may hit even more acutely at private startups that rely on outside investors to keep their operations going.Magic Leap, which counts Alphabet Inc.’s Google and Alibaba Group Holding Ltd. among its largest investors, is gauging potential interest from large tech companies including Facebook Inc. and medical giant Johnson & Johnson, the people said.An initial meeting between Facebook and Magic Leap never progressed to deal talks, according to a person familiar with the matter. The social media giant, already facing rising tariffs and coronavirus-related production pressures for its own virtual reality headsets, isn’t currently interested in acquiring Magic Leap’s business, the person said.AR CompetitionIn addition to Facebook, Microsoft Corp. and Amazon.com Inc. have all been investing in augmented reality with their own divisions, said Jitendra Waral, a Bloomberg Intelligence senior analyst. AR hardware may be limited to enterprise uses for the next several years, he said.For Magic Leap, the valuation of the company will be a question mark because suitors may have to take a long-term bet without substantial near-term revenue, Waral said. The scalability of the company’s technology could also be an issue, he added.“One thing to keep in mind with AR hardware is we do anticipate mainstream adoption being a few years away, so whoever buys them needs to have the financial capacity to carry the products through as AR is still evolving,” he said.Magic Leap’s deliberations, which may not lead to a transaction, come as the company shifts its focus to selling its products to companies in the health-care, industrial and financial sectors after slower-than-expected adoption by consumers.Representatives for Magic Leap, Facebook and J&J declined to comment.Omar Khan, Magic Leap’s chief product officer, said in an interview earlier that the company’s Magic Leap 2 product will be released next year and will help it build a consumer presence. He said he expects the company to develop a disproportionate share of the market, which he said will top $100 billion within a few years.Led by Chief Executive Officer Rony Abovitz, Magic Leap has raised about $2.6 billion from investors and is valued at $6 billion to $8 billion, making it one of the most well-funded tech startups in the U.S. as it built a headset that could project digital objects onto the real world.Among the company’s other big name investors are Japan’s largest wireless operator NTT Docomo Inc., Saudi Arabia’s sovereign wealth fund PIF, Singapore’s state-owned investment company Temasek Holdings Pte. and AT&T Inc.Magic Leap lured investors with a promise to create a headset using spatial computing technologies that offer consumers high-end augmented reality experiences and tools to support remote working. Many big companies have been chasing the same technology, including Microsoft with its HoloLens device.Magic Leap, founded in 2011, unveiled a $2,300 headset in 2018 after years of secretive work and has pledged to deliver technology rivaling television or the telephone in societal impact.Big PromisesThese audacious promises have made Magic Leap the subject of both intense interest and a target for skeptics, who say it has failed to deliver on its early promise and hasn’t met its own sales goals. Attracting a deep-pocketed suitor could buy the company time to roll out future products while allowing investors to cash out.The company has also been looking at raising another $500 million since last year but the round hasn’t closed yet, according to a person familiar. Punchy private valuations for buzzy startups don’t always translate into successful public listings. Two of the most prominent debuts last year -- Uber Technologies Inc. and Lyft Inc. -- are still trading well below their initial public offering prices. Meanwhile, the spectacular collapse of WeWork reads like a cautionary tale for money-losing unicorns headed for public markets.There have also been signs of discord within Magic Leap. The company has faced legal disputes with multiple former employees and Chief Financial Officer Scott Henry stepped down from that role at the end of last year.(Updates with private funding, other listings from third-to-last paragraph.)\--With assistance from Riley Griffin and Joshua Brustein.To contact the reporters on this story: Ed Hammond in New York at ehammond12@bloomberg.net;Sarah Frier in San Francisco at sfrier1@bloomberg.netTo contact the editors responsible for this story: Elizabeth Fournier at efournier5@bloomberg.net, ;Jillian Ward at jward56@bloomberg.net, Michael HythaFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Closely watched opioid trial in New York postponed due to coronavirus
    Reuters

    Closely watched opioid trial in New York postponed due to coronavirus

    The postponement of the March 20 jury trial was a precautionary measure due to the number of people traveling to attend, according to a spokesman for New York Attorney General Letitia James. A new trial was not set but a hearing will be held April 14 to decide next steps in the case, which is in state court in Suffolk County on New York's Long Island.

  • Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates
    Zacks

    Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates

    Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.

  • Johnson & Johnson (JNJ) Stock Moves -1.02%: What You Should Know
    Zacks

    Johnson & Johnson (JNJ) Stock Moves -1.02%: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $142.01, moving -1.02% from the previous trading session.

  • J&J Files MAA for Multiple Sclerosis Drug Ponesimod in Europe
    Zacks

    J&J Files MAA for Multiple Sclerosis Drug Ponesimod in Europe

    Ponesimod's regulatory application in Europe is based on data from the head-to-head OPTIMUM phase III study comparing it to Sanofi's (SNY) MS drug, Aubagio

  • Johnson & Johnson ordered to pay $1.7 million to three Australian women in pelvic mesh class action
    Reuters

    Johnson & Johnson ordered to pay $1.7 million to three Australian women in pelvic mesh class action

    An Australian court on Tuesday ordered Johnson & Johnson to pay three women a total of A$2.6 million ($1.7 million) plus legal costs as compensation for misleading patients and surgeons about the risks of its pelvic mesh implants. The Federal Court of Australia awarded the three lead applicants in the class action lawsuit between A$555,555 and A$1.28 million, the company said. Issues common to the group in the class action, which numbers more than 1,350 women, will be determined in the coming days, paving the way for damages for the other applicants to be determined.

  • J&J ordered to pay $1.7 million to three Australian women in pelvic mesh class action
    Reuters

    J&J ordered to pay $1.7 million to three Australian women in pelvic mesh class action

    An Australian court on Tuesday ordered Johnson & Johnson to pay three women a total of A$2.6 million ($1.7 million) plus legal costs as compensation for misleading patients and surgeons about the risks of its pelvic mesh implants. The Federal Court of Australia awarded the three lead applicants in the class action lawsuit between A$555,555 and A$1.28 million, the company said. Issues common to the group in the class action, which numbers more than 1,350 women, will be determined in the coming days, paving the way for damages for the other applicants to be determined.

  • Reuters - UK Focus

    Trump administration says drug makers will work together to combat coronavirus

    The Trump administration said on Monday it had secured commitments from top pharmaceutical companies to work together to develop a vaccine and treatments to fight the coronavirus. At a meeting with industry executives at the White House, President Donald Trump exhorted the companies to collaborate to speed the process of getting a vaccine and therapeutics to victims of the virus. The White House, which has clashed previously with the pharmaceutical industry over high drug prices and has been struggling in recent weeks to show it is on top of the virus response, saw the meeting as a victory.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more